GNA11
GNA11 (Guanine nucleotide-binding protein subunit alpha-11) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Lung cancer, Melanoma and 1 more.
Overview
Guanine nucleotide-binding proteins (G proteins) function as transducers downstream of G protein-coupled receptors (GPCRs) in numerous signalling cascades. The alpha chain contains the guanine nucleotide binding site and alternates between an active, GTP-bound state and an inactive, GDP-bound state. Signalling by an activated GPCR promotes GDP release and GTP binding.
CIViC holds 9 clinical evidence items and 0 assertions across 5 variants, naming Trametinib, Mirdametinib, Selumetinib and Cabozantinib and others. Open Targets scores its association with cancer at 0.72 (direct and indirect evidence; datatypes affected pathway 0.83, literature 0.90, genetic association 0.00, somatic mutation 0.90, animal model 0.63). IntOGen calls it a driver in 2 cohorts (2 activating, 0 loss-of-function), covering Melanoma, Uveal Melanoma. In OnCo, 1 product record names it (Darovasertib).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · GNA11 (Guanine nucleotide-binding protein subunit alpha-11) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Lung cancer, Melanoma and 1 more.
- 1 · What it is
GNA11 (Guanine nucleotide-binding protein subunit alpha-11) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Lung cancer, Melanoma and 1 more.
- 2 · What goes wrong in cancer
Guanine nucleotide-binding proteins (G proteins) function as transducers downstream of G protein-coupled receptors (GPCRs) in numerous signalling cascades.
- 3 · How drugs use it
No product in this corpus aims at GNA11 yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
External identifiers
Sources: HGNC HGNC:4379 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P29992 (protein name, function text, keywords and locations (REST API)); CIViC gene GNA11 (9 evidence items, 0 assertions, 5 variants; diseases: Uveal Melanoma, Cancer, Congenital Hemangioma (GraphQL API, CC0)); Open Targets ENSG00000088256 (association with cancer (MONDO_0004992) 0.72; per-cancer scores at or above 0.5: melanoma 0.71, skin cancer 0.62, ocular melanoma 0.63, lung cancer 0.51 (GraphQL API, CC0)); IntOGen GNA11 (driver in 2 cohorts (Act 2, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Guanine nucleotide-binding proteins (G proteins) function as transducers downstream of G protein-coupled receptors (GPCRs) in numerous signalling cascades. The alpha chain contains the guanine nucleotide binding site and alternates between an active, GTP-bound state and an inactive, GDP-bound state. Signalling by an activated GPCR promotes GDP release and GTP binding. The alpha subunit has a low GTPase activity that converts bound GTP to GDP, thereby terminating the signal. Both GDP release and GTP hydrolysis are modulated by numerous regulatory proteins. Signalling is mediated via phospholipase C-beta-dependent inositol lipid hydrolysis for signal propagation: activates phospholipase C-beta: following GPCR activation, GNA11 activates PLC-beta (PLCB1, PLCB2, PLCB3 or PLCB4), leading to production of diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). Location: Cell membrane; Cytoplasm (UniProt). Locus 19p13.3 (HGNC).
- Skin cancer: Open Targets association 0.62 with skin cancer (MONDO_0002898)
- Lung cancer: Open Targets association 0.51 with lung cancer (MONDO_0008903)
- Melanoma: Open Targets association 0.71 with melanoma (MONDO_0005105); IntOGen driver in 1 cohort (MEL)
- Uveal melanoma: Open Targets association 0.63 with ocular melanoma (MONDO_0006325); CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 6 therapies; IntOGen calls it an activating (Act) driver in 2 cohorts; CIViC holds 9 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Congenital Hemangioma.
Latest papers
topQuery for this target: (TITLE:"GNA11" OR ABSTRACT:"GNA11" OR TITLE:"G protein subunit alpha 11" OR ABSTRACT:"G protein subunit alpha 11" OR TITLE:"Guanine nucleotide-binding protein subunit alpha-11" OR ABSTRACT:"Guanine nucleotide-binding protein subunit alpha-11" OR TITLE:"FBH2" OR ABSTRACT:"FBH2" OR TITLE:"FHH2" OR ABSTRACT:"FHH2" OR TITLE:"HHC2" OR ABSTRACT:"HHC2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about GNA11, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetCBLB
Shares Lung cancer (all types), Skin cancer (all types), CIViC, IntOGen.
- TargetCRLF2
Shares Lung cancer (all types), Skin cancer (all types), CIViC, IntOGen.
- TargetGNAQ
Shares Darovasertib, Uveal melanoma, Skin cancer (all types), CIViC.
- TargetNKX2-1
Shares Lung cancer (all types), Skin cancer (all types), IntOGen, Melanoma.
- TargetCDX2
Shares Lung cancer (all types), Skin cancer (all types), CIViC, IntOGen.
- TargetCIITA
Shares Lung cancer (all types), Skin cancer (all types), CIViC, IntOGen.
- TargetSMAD3
Shares Lung cancer (all types), Skin cancer (all types), CIViC, IntOGen.
- TargetEIF1AX
Shares Uveal melanoma, Lung cancer (all types), CIViC, IntOGen.